主页 > 医学信息 >
【drug-news】08年Q1药厂财务报表陆续公布
AP J&J posts 40 percent jump in 1Q profit
Tuesday April 15, 12:28 pm ET
By Linda A. Johnson, AP Business Writer
Strong sales, exchange rates help boost Johnson & Johnson's profit by 40 pct in 1st quarter
TRENTON, N.J. (AP) -- Health products maker Johnson & Johnson reported a 40 percent jump Tuesday in its first-quarter profit, mainly due to the weak dollar boosting foreign revenues and a research charge taken a year ago.
The New Brunswick, N.J.-based maker of contraceptives, medical devices, baby care items and prescription drugs reported net income of $3.6 billion, or $1.26 per share, for the first three months of the year, up from $2.57 billion, or 88 cents a share, a year ago. The year-ago quarter included a charge of $807 million for research and development related to the acquisition of Conor Medsystems Inc., a developer of stents.
Revenues rose 7.7 percent to $16.19 billion from $15.04 billion a year earlier, primarily due to higher sales of consumer health care products such as baby and skin care products in the Listerine line.
Analysts surveyed by Thomson Financial were expecting lower earnings of $1.20 a share on revenue of $15.83 billion.
Despite beating Wall Street estimates, J&J shares were down 47 cents at $65.27 in midday trading, roughly in the middle of the company's 52-week trading range of $59.72 to $68.85.
"This is an anemic report. It is the harbinger of, unfortunately, worse things to come" for J&J and the entire pharmaceutical industry, said analyst Steve Brozak of WBB Securities Ltd. "This (earnings) statement is proof positive that we are in a recession, no ifs, ands or buts about it."
Most sales growth was in the consumer health care division, he noted, not in the high-margin pharmaceuticals division.
Sales of consumer health products jumped 16 percent to $4.06 billion, driven partly by the recent launch of nonprescription allergy drug Zyrtec. Sales of prescription drugs increased only 3.3 percent, to $6.43 billion, and revenues from medical devices and diagnostics rose 7.2 percent to $5.7 billion, with nearly all of those increase coming from sales overseas.
In all three divisions, 11 percent or more of overseas revenue growth -- nearly all the growth -- came from favorable currency exchange rates. Overall, they boosted total revenues by 5.1 percent for J&J, the world's No. 6 pharmaceutical company, according to IMS Health.
In the United States, revenue growth was only 0.2 percent in the medical devices and diagnostics division, and 0.9 percent for pharmaceuticals, Brozak noted.
"It was as anemic as you can get without being negative," he said, due to lack of major new products and significantly lower sales of J&J's anemia drug Procrit and its stents -- tiny metal scaffolds that prop open arteries after they are unclogged.
J&J's chief financial officer, Dominic Caruso, told analysts during a conference call that the company now expects earnings per share for 2008 to total $4.40 to $4.45, excluding one-time items, up a penny from the $4.39 to $4.44 forecast it gave in January.
He noted that the cost-savings program begun last July has already begun to affect operating costs, partly offsetting the continued impact of generic competition.
"We continue to invest in growth opportunities that are critical to our future and are continuing to manage our costs," he said.
On the Net: http://www.jnj.com 基因技术公司（Genentech）4月10日公布2008年第一季度业绩报告。受到抗肿瘤药物产品销售强劲的有利推动，本季度基因技术公司净收益大幅度增长12%，达7.90亿美元。拳头产品抗肿瘤药贝伐单抗（bevacizumab，阿瓦斯丁，Avastin）本季度销售收入攀升13%，为6亿美元，略低于分析师预期值6.22亿美元。
本季度抗肿瘤药物利妥昔单抗（rituximab，美罗华，Rituxan）销售收入增长13%，为6.05亿美元。抗肿瘤药群司珠单抗（trastuzumab，赫塞汀，Herceptin）销售收入增长9%，为3.39亿美元。湿性老年性黄斑病变（wet age-related macular degeneration，AMD）治疗药物ranibizumab（Lucentis）销售收入下跌6%，为1.98亿美元。整体而言，基因技术公司本季度销售收入增长8%，为31亿美元。
本季度基因技术的表现好于预期，Avastin显然是个亮点。据了解，美国FDA已经于今年2月批准本品用于治疗乳腺癌，但姗姗来迟的获批公告对本季度公司业绩并未形成显著影响，然而本品前景可期。基因技术表示，Avastin用于治疗复发性多形性恶性胶质瘤的申请有望于今年下半年获批。
另据悉，基因技术公司重申2008年财务预期，预计全年每股收益将达到3.35～3.45美元（不计特殊项目开支）。
(中国医药数字图书馆网站) 默克股票第一季度下滑35%
Merck could face tough 1Q on Vytorin, Singulair concerns
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-09-27 17:11
医学,生命科学网